Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-165

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-165). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure of losartan potassium, depicting molecular bonds, rings, and functional groups including a potassium ion (K+).*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line graph comparing the percentage of patients with primary endpoint over study months for Losartan potassium and Atenolol. The x-axis represents study months up to 66, and the y-axis shows percentage of patients up to 16%. Losartan potassium is shown with a solid line, Atenolol with a dotted line, indicating a 13% adjusted risk reduction for Losartan (p=0.021).*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A line graph comparing the percentage of patients experiencing fatal or non-fatal strokes over a study period of 66 months between two drugs: Atenolol (dotted line) and Losartan potassium (solid line). The graph shows a lower cumulative incidence for Losartan potassium, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A comparative forest plot chart showing hazard ratios with 95% confidence intervals for event rates of Losartan Potassium versus Atenolol across various patient subgroups. The chart is divided into two sections: Primary Composite and Stroke (Fatal/Non-fatal), with subcategories by age, gender, race, isolated systolic hypertension (ISH), diabetes status, and history of cardiovascular disease (CVD). Event rates (%) and hazard ratios are displayed to indicate relative treatment effects, with markers showing favorability towards Losartan Potassium or Atenolol.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A line graph comparing the percentage of patients with events over 48 months between losartan potassium and placebo groups. The x-axis represents time in months, and the y-axis shows the percentage of patients with events. The solid line represents losartan potassium, and the dotted line represents placebo, indicating a risk reduction of 16.1% with losartan potassium (p=0.022).*

FDA Label Image

72789163 Label (72789163)

Losartan Potassium 25 mg Tablets, USP film-coated tablets in a 90-count package. The label includes the NDC 72789-163-90, marked Rx only, and states it is marketed by PD-Rx Pharmaceuticals, Inc., and manufactured by Vivimed Life Sciences Private Limited in Tamilnadu, India. Storage instructions and a barcode are also included.*

FDA Label Image

72789164 Label (72789164)

Label for Losartan Potassium 50 mg tablets, USP, containing 90 film-coated tablets for oral use. Marketed and packaged by PD-Rx Pharmaceuticals, Inc. in Oklahoma City, OK, and manufactured by Vivimed Life Sciences Private Limited in Tamilnadu, India. The label includes storage instructions, barcode, NDC 72789-164-90, and a note for pharmacists to dispense with a medication guide.*

FDA Label Image

72789165 Label (72789165)

Label for Losartan Potassium Tablets USP 100 mg, containing 90 tablets. The label shows the product name, strength, and quantity along with storage instructions, bar code, and distributor information. Marketed by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK, and manufactured by Vivimed Life Sciences Private Limited, Tamilnadu, India. The label includes an NDC number and a notice for pharmacists to dispense with a medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.